ABP 710: Withdrawal of the marketing authorisation application



Amgen Europe B.V. withdrew its application for a marketing authorisation of ABP 710 for the treatment of inflammatory diseases.

The company withdrew the application on 27 May 2019.

Key facts

ABP 710
Product number
International non-proprietary name (INN) or common name
  • infliximab
Active substance
  • infliximab
Date of withdrawal
Company making the application
Amgen Europe B.V.
Withdrawal type
Initial authorisation

Related information on withdrawals

A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

How useful was this page?

Add your rating
1 rating